The intestinal microbiota and susceptibility to infection in immunocompromised patients
- PMID: 23806896
- PMCID: PMC4485384
- DOI: 10.1097/QCO.0b013e3283630dd3
The intestinal microbiota and susceptibility to infection in immunocompromised patients
Abstract
Purpose of review: Many infections of immunocompromised patients originate from the gastrointestinal tract. The pathogenesis of these infections often begins with alteration of the intestinal microbiota. Understanding the microbiota and how it can either cause or prevent infection is vital for the development of more effective prevention and treatment of these infections. This article reviews and discusses recent work providing insight into the intestinal microbiota of these at-risk immunocompromised patients.
Recent findings: Studies continue to support the premise that commensal bacteria, largely anaerobic, serve to maintain microbial stability and colonization resistance by preventing overgrowth or domination with more pathogenic bacteria, through interactions within the microbial community and with the host. In patients with immune suppression due to high-dose chemotherapy or hematopoietic stem cell transplantation, disruption of the microbiota through antibiotics as well as impairment of host immunity gives rise to perturbations favoring intestinal domination by pathogenic species, leading to increased bacterial translocation and susceptibility to systemic infection.
Summary: An understanding of the intestinal microbiota and the impact of antibiotics will help to guide our treatment of these gut-originating infections.
Conflict of interest statement
References
-
- Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, Kern WV. Antibiotic prophylaxis in neutropenic patients. Cancer. 2006;107:1743–1751. - PubMed
-
- Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie T, van de Wetering M, Kremer L, Leibovici L. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy (Review) 2012 [no volume]. Meta-analysis of antibiotic prophylaxis for fever and neutropenia, updated from the original meta-analysis in 2005. This is the clearest evidence of mortality benefit for fluoroquinolone prophylaxis. - PMC - PubMed
-
- Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D'Antonio D, Buelli M, Nosari AM, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. New England Journal of Medicine. 2005;353:977–987. - PubMed
-
- Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JAH, Wingard JR, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011;52:e56–93. - PubMed
-
- Jaffe D, Jakubowski A, Sepkowitz K, Sebti R, Kiehn TE, Pamer E, Papanicolaou GA. Prevention of peritransplantation viridans streptococcal bacteremia with early vancomycin administration: a single-center observational cohort study. Clinical infectious diseases. 2004;39:1625–1632. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
